Home » Stocks » TORC

resTORbio, Inc. (TORC)

Sep 16, 2020 - Stock symbol was changed to ACET
Stock Price: $15.40 USD 13.12 (575.44%)
Updated Sep 16, 2020 4:00 PM EDT
Market Cap 83.11M
Revenue (ttm) n/a
Net Income (ttm) -65.98M
Shares Out 36.45M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Sep 16, 2020
Last Price $15.40
Previous Close $2.28
Change ($) 13.12
Change (%) 575.44%
Day's Open 2.38
Day's Range 14.56 - 16.09
Day's Volume 101,708
52-Week Range 0.86 - 16.09

News

Hide News
GlobeNewsWire - 4 months ago

- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology -

GlobeNewsWire - 5 months ago

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to preve...

PRNewsWire - 5 months ago

NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a coll...

GlobeNewsWire - 5 months ago

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-...

PRNewsWire - 6 months ago

NEW YORK, June 29, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of resTORbio, Inc. ("TORC" or th...

Seeking Alpha - 8 months ago

ResTORbio's Reverse Merger With Adicet Should Unlock Substantial Value For Shareholders

GlobeNewsWire - 8 months ago

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and we...

GlobeNewsWire - 9 months ago

BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...

Seeking Alpha - 1 year ago

ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash

The Motley Fool - 1 year ago

The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.

24/7 Wall Street - 1 year ago

There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket.

GlobeNewsWire - 1 year ago

Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults Analysis indicates RTB101 upr...

GlobeNewsWire - 1 year ago

BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to pre...

Seeking Alpha - 1 year ago

TORC has done tolerably well since IPO-ing last year, producing solid phase 2 results from lead drug candidate RTB101.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in resTORbio.

About TORC

resTORbio, a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to tr... [Read more...]

Industry
Biotechnology
IPO Date
Jan 26, 2018
CEO
Chen Schor
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
TORC
Full Company Profile

Financial Performance

Financial Statements